Tianjin Development Holdings Limited (TIANJIN DEV, 00882.HK) released the unaudited results of its 34.12%-owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd., for the three months ended 31 March 2026.
Revenue and operating performance • Q1 revenue fell 10.17% year-on-year to RMB 332.28 million (Q1 2025: RMB 369.84 million). • Total operating costs decreased 9.77% to RMB 275.93 million, broadly in line with the revenue contraction. • Selling expenses dropped 29.21% to RMB 77.81 million, while R&D expenditure declined 35.04% to RMB 19.98 million, indicating tighter cost control. • Net finance income shrank sharply: a net gain of RMB 6.34 million versus RMB 29.23 million a year earlier, mainly due to lower interest income.
Profitability • Operating profit slipped 7.19% to RMB 62.38 million. • Net profit attributable to parent shareholders decreased 6.15% to RMB 51.88 million; total net profit was RMB 53.07 million. • Basic and diluted earnings per share both declined to RMB 0.20 (Q1 2025: RMB 0.21). • Other comprehensive income of RMB 2.44 million lifted total comprehensive income to RMB 55.50 million.
Balance-sheet highlights (31 Mar 2026 vs. 31 Dec 2025) • Total assets: RMB 5.53 billion, down 0.92%. • Total liabilities: RMB 893.57 million, down 3.28%; liability-to-asset ratio stood at 16.15%. • Equity attributable to owners: RMB 4.61 billion, edging down 0.48%. • Cash-equivalent data were not disclosed, but treasury shares remained at RMB 85.77 million.
These figures relate solely to Tianjin Lisheng Pharmaceutical and do not represent the consolidated results of TIANJIN DEV.
Comments